The PTCE blueprint is split across 4 domains. Weights are the official share of the exam; see the official exam guide for the authoritative breakdown.
What you must be able to do. Recall a drug's generic and brand names, class, indication, and common interactions on sight, and spot a duplicate therapy, a contraindication, or a storage and stability requirement from a short scenario.
In one sentenceThe largest domain by far: knowing the drugs themselves - names, classes, indications, interactions, side effects, and how to store and handle them safely.
Recall check: answer these from memory first
- Give the generic name, drug class, and main indication for three of: Lipitor, Glucophage, Coumadin, Ventolin.
- Name one common drug-drug interaction that is genuinely dangerous, and say which two drug groups are involved.
- Which common medications must be refrigerated, and which of those must never be frozen?
What it tests. The medications themselves, which is the knowledge the rest of the exam leans on. Generic and brand names and the classifications that group them; therapeutic duplications in a regimen and when they need flagging; common and life-threatening interactions and contraindications across drug-drug, drug-supplement, drug-laboratory, drug-nutrient, and drug-disease; strengths and doses, dosage forms, routes of administration, and special handling; common and severe side effects, adverse effects, and allergies; therapeutic indications; drug stability for suspensions, insulins, reconstitutables, injectables, and vaccines; and proper storage by temperature, light sensitivity, and restricted access.
How to study it. This is the heaviest domain, so give it the most time. Learn drugs in their classes rather than one by one, because the class usually carries the indication, the headline side effects, and the interaction pattern: learn what an ACE inhibitor does and you have a head start on every drug ending in -pril. Drill brand to generic both directions until it is instant, since the exam names a drug either way. Build a short interactions list of the ones that genuinely hurt, such as warfarin with NSAIDs or an MAOI with a serotonergic drug, and keep storage simple by the exceptions: most refrigerated items live at 2 to 8 degrees Celsius, so learn what must stay cold and what must never freeze rather than memorising every value.
Easy to confuse
- Generic name versus brand name. The generic name is the single, lowercase drug name (atorvastatin); the brand name is a manufacturer's capitalised trademark (Lipitor). One generic can have several brands, so the exam names a drug either way and expects you to match them.
- Therapeutic class versus therapeutic duplication. A therapeutic class groups drugs by what they treat or how they work; a therapeutic duplication is two drugs from the same class on one regimen doing the same job. The class is the label; the duplication is the safety problem you flag.
- Side effect versus allergy. A side effect is an expected, dose-related response (a statin causing muscle ache); an allergy is an immune reaction (hives, swelling, anaphylaxis). Recording nausea as an allergy is wrong, and the exam tests that you separate the two.
Worked example from the PTCE bank
lock_openFree sampleMedicationshard
A patient, Renata Fairburn, presents a new prescription for the macrolide clarithromycin to treat a respiratory infection. Her active profile shows she takes simvastatin 40 mg each evening for hyperlipidaemia. The technician is reviewing the profile before the pharmacist verifies the order. Which interaction concern should the technician flag as the PRIMARY safety issue?
- AClarithromycin inhibits the metabolism of simvastatin, raising the risk of myopathy and rhabdomyolysis.check_circle Correct
- BClarithromycin reduces the absorption of simvastatin, making the statin therapeutically ineffective.
- CClarithromycin and simvastatin compete for renal excretion, causing the antibiotic to accumulate to toxic levels.
- DClarithromycin chelates with simvastatin in the gut, forming an inactive complex that passes unabsorbed.
Recognise that strong CYP3A4 inhibitors such as clarithromycin raise levels of CYP3A4-metabolised statins and increase myopathy risk. Simvastatin relies on CYP3A4 for clearance. Clarithromycin potently inhibits CYP3A4, so plasma simvastatin concentrations rise sharply, and elevated exposure is the mechanism that drives dose-dependent muscle toxicity including rhabdomyolysis.
Why A is correct: Clarithromycin is a strong CYP3A4 inhibitor and simvastatin is a CYP3A4 substrate, so co-administration markedly raises simvastatin levels and the risk of muscle injury, which is the correct primary flag.
Why B is wrong: This is tempting because absorption interactions exist for some drugs, but the clarithromycin-simvastatin interaction is metabolic inhibition that raises, not lowers, statin exposure, so this is wrong.
Why C is wrong: A renal competition mechanism sounds plausible, but the recognised concern is hepatic CYP3A4 inhibition affecting the statin, not antibiotic accumulation, so this misstates the mechanism.
Why D is wrong: Chelation is a real interaction type for tetracyclines and divalent cations, which makes it familiar, but it does not apply to this macrolide and statin pair, so this is incorrect.
What you must be able to do. Apply the federal rule that governs a controlled substance, a restricted-drug programme, a recall, or a disposal step, and pick the action that keeps the pharmacy compliant.
In one sentenceThe law layer: DEA controlled-substance schedules and paperwork, restricted-drug programmes like REMS and pseudoephedrine limits, FDA recalls, hazardous-waste disposal, and supply-chain tracing.
Recall check: answer these from memory first
- Which DEA schedules permit refills, how many, and within what period?
- State the federal pseudoephedrine daily and 30-day sales limits, and name the law behind them.
- Name the three FDA recall classes and say which one means a reasonable probability of serious harm or death.
What it tests. Pharmacy practice as federal law constrains it. Storage, handling, and disposal of non-hazardous, hazardous (such as P-list), and pharmacological wastes; controlled-substance prescriptions across new, refill, and transfer, and the DEA schedules from II to V; the controlled-substance lifecycle of receiving, storing, ordering, labelling, dispensing, returning, take-back, loss or theft, and destruction; restricted-drug programmes including pseudoephedrine sales limits and REMS such as iPLEDGE and clozapine; FDA medication recalls and their classes; and product serialisation, tracking, tracing, and quarantine under the Drug Supply Chain Security Act.
How to study it. This domain is rules, so it is reliable marks once you organise it. Build a schedule table you can recall cold: which schedules allow refills and how many, the difference in handling between Schedule II and the rest, and which form, the DEA Form 222, orders Schedule II stock. Learn the pseudoephedrine limits as concrete numbers (the 3.6 grams per day and 9 grams per 30 days thresholds) because the exam asks them directly. Match each named REMS to its drug, since iPLEDGE means isotretinoin and clozapine REMS means white-cell monitoring. For recalls, learn the three classes by severity, with Class I as the dangerous one.
Easy to confuse
- Schedule II versus Schedules III to V. Schedule II drugs allow no refills and need a DEA Form 222 (or its electronic equivalent) to order; Schedule III and IV allow up to five refills within six months, while Schedule V is refillable as the prescriber authorises. The exam keys many controlled-substance questions on this single line.
- REMS versus a standard prescription requirement. A REMS is an extra, drug-specific safety programme the FDA mandates (iPLEDGE for isotretinoin, monitoring for clozapine); an ordinary prescription requirement applies to everything. If the drug is named with a special enrolment, lab, or dispensing limit, it is REMS.
- Class I versus Class III recall. A Class I recall means a reasonable probability of serious harm or death; a Class III recall is unlikely to cause harm (a labelling or minor quality fault). The severity decides how fast the pharmacy must pull stock, so the class is the answer the question wants.
Worked example from the PTCE bank
lock_openFree sampleFederal Requirementshard
A patient, Marisol Quintero, presents a written prescription for oxycodone immediate-release 5 mg, quantity 60, signed by Dr Aimee Voss. The patient asks the technician to fill only 20 tablets today because she cannot afford the full quantity, and to receive the balance later. What is the technician's BEST action under federal law?
- ADispense the partial quantity of 20 tablets and supply the remaining 40 tablets within 30 days of the prescription date.check_circle Correct
- BDispense the partial quantity of 20 tablets and supply the balance only within 72 hours, after which the remainder is void.
- CRefuse the partial fill because Schedule II prescriptions must be dispensed in full or returned to the patient.
- DDispense 20 tablets now and add five refills so the patient may collect the remaining tablets as needed.
A Schedule II prescription partially filled at the patient's request may be completed within 30 days of the written date, with no refills permitted. Federal rules allow a partial fill of a Schedule II prescription when the patient or prescriber requests it; the pharmacy may supply the remaining amount within 30 days of the issue date, whereas the separate 72-hour limit governs partials due to insufficient stock.
Why A is correct: Correct: federal law permits partial filling of a Schedule II prescription at the patient's request, and the remaining quantity may be supplied within 30 days of the date the prescription was written.
Why B is wrong: Tempting because the 72-hour limit is a genuine Schedule II partial-fill provision, but under current federal law a partial fill requested by the patient must be completed within 30 days of the written date, so the shorter 72-hour deadline is not the operative rule for this patient-requested partial.
Why C is wrong: Tempting because Schedule II carries no refills, but partial filling at the patient's request is expressly permitted, so an outright refusal is not required.
Why D is wrong: Tempting because refills feel like a way to spread out collection, but Schedule II prescriptions may not be refilled at all, so authorising refills is unlawful.
What you must be able to do. Spot the high-alert or look-alike risk in a scenario, apply the error-prevention rule that defuses it, and route to pharmacist intervention or formal reporting when the situation calls for it.
In one sentenceThe safety layer: high-alert and look-alike/sound-alike drugs, the error-prevention rules that catch mistakes, when to involve the pharmacist, and how to report what goes wrong.
Recall check: answer these from memory first
- State the leading-zero and trailing-zero rules, and explain why each prevents a tenfold dosing error.
- Name four high-alert medication classes that cause the most serious harm when given in error.
- Which adverse events go to VAERS and which go to MedWatch?
What it tests. Keeping patients safe and improving quality. High-alert and high-risk medications and look-alike/sound-alike (LASA) pairs; error-prevention strategies including correct-patient verification, Tall Man lettering, inventory separation, leading and trailing zeros, bar codes, and avoiding error-prone abbreviations; recognising issues that need pharmacist intervention, from drug utilisation review and adverse events to OTC advice, therapeutic substitution, adherence, and interactions; event reporting through MedWatch and VAERS, near misses, root-cause analysis, and continuous quality improvement; the types of prescription error (dose, quantity, patient, drug, route); and infection prevention through handwashing, PPE, and equipment cleaning.
How to study it. Learn the safety rules as concrete habits, because the exam tests their application, not their names. Fix the zeros rule firmly: always a leading zero before a decimal (0.5 mg, never .5 mg) and never a trailing zero after one (5 mg, never 5.0 mg), since both are classic tenfold-overdose traps. Memorise the headline high-alert drugs (insulin, anticoagulants such as warfarin and heparin, opioids, concentrated electrolytes like potassium chloride) because they cause the most serious harm. Learn the reporting routes by purpose: MedWatch for drug and device problems, VAERS for vaccine adverse events. And know the firm line on scope: anything clinical, a DUR alert, an interaction, an OTC recommendation, goes to the pharmacist.
Easy to confuse
- Leading zero versus trailing zero. Always write a leading zero before a decimal point (0.5 mg) so the point is not missed; never write a trailing zero after one (write 5 mg, not 5.0 mg) so it is not read as 50. Both rules exist to stop a tenfold dose error, and the exam tests them as opposites.
- MedWatch versus VAERS. MedWatch is the FDA system for drug, biologic, and device problems; VAERS is the dedicated system for vaccine adverse events. If a vaccine is named, it is VAERS; for everything else medication-related, it is MedWatch.
- High-alert medication versus LASA pair. A high-alert medication causes serious harm when used in error regardless of its name (insulin, heparin); a look-alike/sound-alike pair is two drugs confused because their names or packaging resemble each other (hydralazine and hydroxyzine). One is about consequence; the other is about confusion.
Worked example from the PTCE bank
lock_openFree samplePatient Safety and Quality Assurancemedium
A technician is entering a new prescription for an injectable opioid into the pharmacy system. The prescriber wrote the dose as ".5 mg" on the order. To reduce the risk of a tenfold dosing error before the entry is verified, how should the technician record the strength?
- AEnter it as "0.5 mg", adding a leading zero before the decimal point.check_circle Correct
- BEnter it exactly as written, ".5 mg", so the record matches the original order character for character.
- CEnter it as "0.50 mg", adding both a leading zero and a trailing zero for clarity.
- DEnter it as ".50 mg", keeping the prescriber's format and adding a trailing zero.
Doses below one should carry a leading zero and never a trailing zero to prevent tenfold and hundredfold misreadings. A decimal point can be missed in handwriting, faxes, or screens. A leading zero gives the eye a clear marker that a fraction follows, while a trailing zero adds a digit that, if the point is lost, inflates the value, so safe practice requires the leading zero and forbids the trailing one.
Why A is correct: A leading zero before a bare decimal point makes the decimal far less likely to be overlooked, so "0.5 mg" cannot be misread as "5 mg"; this is the recommended safe practice.
Why B is wrong: Copying the naked decimal is tempting because faithful transcription feels safe, but a missed decimal point makes ".5" read as "5", causing a tenfold overdose, which is precisely the error a leading zero prevents.
Why C is wrong: The leading zero is correct, but the trailing zero is unsafe because if the decimal point is missed "0.50" can be read as "50 mg", a hundredfold error, so trailing zeros are discouraged.
Why D is wrong: This keeps the dangerous naked decimal and adds a trailing zero, combining the two formatting errors that the leading-zero and no-trailing-zero conventions are designed to eliminate.
What you must be able to do. Read a prescription's Sig, run the calculation it implies (days supply, quantity, dose, concentration, or dilution) exactly, select the right equipment, and interpret the codes on the packaging.
In one sentenceThe mechanics of the order: translating Sig codes, doing the core pharmacy calculations exactly, choosing the right equipment, and reading lot numbers, expiry dates, and NDCs.
Recall check: answer these from memory first
- Decode this Sig and give the days supply: 'i tab po bid', 60 tablets dispensed.
- You need 100 mL of a 5% solution from a 25% stock. How many mL of stock do you draw, and what is the working?
- Name the three segments of an NDC number and say what each identifies.
What it tests. Turning a prescription into a correct, processed order. Formulas, ratios, proportions, conversions, Sig codes, abbreviations, and symbols to work out days supply, quantity, dose, concentration, and dilutions; selecting equipment and supplies for administration, from diabetic supplies and inhaler spacers to oral and injectable syringes, filters, dilution solutions, and nebulisers; interpreting lot numbers, expiration dates, and National Drug Code (NDC) numbers on packaging; and the procedures for returning dispensable, non-dispensable, and expired medications through credit return, return to stock, and reverse distribution.
How to study it. This domain is calculation and code-reading, so practise it by hand until it is automatic. Learn the common Sig codes cold (bid is twice daily, tid three times, qd once daily, prn as needed, po by mouth) because every days-supply question starts by decoding the Sig. Drill one method per calculation type and keep the units labelled. For days supply, divide the total quantity by the amount used per day: 90 tablets at 1 tablet three times daily is 90 divided by 3, which is 30 days. For dilution, hold strength times volume constant on both sides. Learn the NDC as its three segments (labeller, product, package) and treat the returns rules as a short decision: saleable stock can go back, expired or opened stock goes to reverse distribution.
Easy to confuse
- Days supply versus quantity to dispense. Days supply is how long a quantity lasts (total amount divided by daily use); quantity to dispense is how much to give for a target number of days (daily use times days). They are inverse calculations, and the exam states which one it wants in the last line.
- Concentration versus dilution. A concentration calculation finds how much drug is in a volume (a percentage or ratio strength); a dilution calculation finds how much stock and diluent give a weaker target, holding the amount of pure drug constant. Dilution always has a before and an after strength; concentration has one.
- Return to stock versus reverse distribution. Return to stock puts a still-saleable, never-dispensed medication back on the shelf; reverse distribution sends expired, recalled, or non-saleable stock to a licensed processor for credit and destruction. Saleable goes back; non-saleable goes out.
Worked example from the PTCE bank
lock_openFree sampleOrder Entry and Processinghard
A technician at Birchwood Pharmacy receives a prescription for Lerato Mokoena: latanoprost 0.005% ophthalmic solution, one drop into each eye every evening, dispensed as a single 2.5 mL bottle. Using the standard estimate that an ophthalmic dropper delivers about 20 drops per millilitre, what days supply should the technician enter for this dispense?
- AAbout 50 days, treating each bottle as delivering one drop per day total.
- BAbout 25 days, based on two drops used each day from roughly 50 drops in the bottle.check_circle Correct
- CAbout 12 days, counting four drops into each eye every evening.
- DAbout 30 days, rounding the bottle to a convenient monthly figure.
Calculate ophthalmic days supply by converting bottle volume to drops and dividing by the total daily drops across all dosed eyes. Days supply for drops equals total drops in the container divided by drops used per day. A 2.5 mL bottle at 20 drops per mL holds about 50 drops, and dosing one drop into each of two eyes once daily uses two drops per day, giving 50 divided by 2, or about 25 days.
Why A is wrong: This counts only one drop daily and ignores that both eyes are dosed, so it doubles the true supply by halving the daily drop count.
Why B is correct: The 2.5 mL bottle yields about 50 drops, and one drop per eye each evening is two drops per day, so 50 divided by 2 gives roughly 25 days.
Why C is wrong: This misreads the directions as four drops per eye; the sig states one drop per eye, so it overstates daily use and understates the supply.
Why D is wrong: Rounding to a calendar month ignores the actual drop maths; 30 days would require fewer than two drops daily, which the sig does not support.